首页 | 本学科首页   官方微博 | 高级检索  
检索        

生脉注射液对创伤失血性休克大鼠免疫功能的影响
引用本文:刘星,王毅鑫,苏文利.生脉注射液对创伤失血性休克大鼠免疫功能的影响[J].中国医药导报,2012,9(2):34-36.
作者姓名:刘星  王毅鑫  苏文利
作者单位:1. 上海长征医院心内科,上海,200003
2. 上海中医药大学附属普陀医院急诊科,上海,200062
基金项目:上海市卫生局医学重点专科主攻课题(No.05110182-1)
摘    要:目的探讨生脉注射液对创伤失血性休克大鼠T淋巴细胞及其亚群的影响,为揭示生脉注射液调理创伤后免疫功能紊乱机制提供依据。方法制作创伤失血性休克大鼠模型。将30只SD大鼠随机分为3组,分别为正常对照组(A组)、创伤失血性休克组(B组)、生脉注射液治疗组(C组),每组各10只。3组大鼠分别于实验开始后第3天处死。全自动血液生化仪检测大鼠血常规,流式细胞仪检测T淋巴细胞及其亚群(CD3^+、CD4^+、CD8^+)含量。结果大鼠创伤失血性休克后,机体出现过度的炎症反应和免疫功能低下状态,B组与A组比较,白细胞含量显著升高(8.890±0.387)×10^9/L vs(4.230±0.856)×10^9/L,P=0],中性粒细胞比例显著升高(26.15±2.97)%vs(16.00±4.53)%,P=0],淋巴细胞比例显著下降(68.57±5.23)%vs(76.617±4.9)%,P=0.001]。应用生脉注射液治疗后,C组与B组比较,白细胞明显下降(6.29±0.758)×10^9/L vs(8.89±0.387)×109/L,P=0],中性粒细胞比例显著下降(20.29±3.09)%vs(26.15±2.97)%,P=0.001],同时,淋巴细胞比例显著上升(74.85±4.12)%vs(68.57±5.23)%,P=0.007]。创伤失血性休克后,B组与A组相比,大鼠CD3^+、CD4^+T淋巴细胞数量显著降低CD3+:(31.17±4.00)vs(41.97±2.50),P=0;CD4^+:(10.49±1.42)vs(15.51±3.48),P=0.003],CD4^+/CD8^+比值降低(0.97±0.09)vs(1.19±0.07),P=0],CD8+含量变化差异无统计学意义(17.75±5.94)vs(17.34±3.77),P=0.997]。大鼠处于免疫功能抑制状态,在生脉注射液治疗后,C组与B组比较,CD3^+、CD4^+T细胞数量显著升高CD3^+:(36.64±5.73)vs(31.17±4.00),P=0.001;CD4^+:(10.49±1.42)vs(13.94±2.02),P=0.008],CD4^+/CD8^+比值有所升高(1.12±0.03)vs(0.97±0.09),P=0.001]。结论创伤失血性休克大鼠出现炎症反应和T淋巴细胞免疫功能下降,应用生脉注射液能明显提高创伤失血性休克大鼠T淋巴细胞的免疫功能,降低炎症反应。

关 键 词:创伤失血性休克  生脉注射液  淋巴细胞  免疫功能

Experimental study on the immunomodulating effects of Shengmai Injection in severe trauma rats with hemorrhagic shock
LIU Xing,WANG Yixin,SU Wenli.Experimental study on the immunomodulating effects of Shengmai Injection in severe trauma rats with hemorrhagic shock[J].China Medical Herald,2012,9(2):34-36.
Authors:LIU Xing  WANG Yixin  SU Wenli
Institution:1.Department of Cardiology,Changzheng Hospital of Shanghai,Shanghai 200003,China;2.Department of Emergency,Putuo Affiliated Hospital of Shanghai University of Traditional Chinese Medicine,Shanghai 200062,China
Abstract:Objective To study the inference on the of Shengmai Injection in T lymphocytes of severe trauma rats with hemorrhagic shock,in order to provide the experiment evidence for immune dysfunction mechanism after using Shengmai Injection.Methods Animal models of severe trauma hemorrhage shock by bloodletting add cutting of femur were mode.In view of the paradox in immune function after severe trauma hemorrhage shock,30 SD(Sprague-Dawley) rats were divided into normal control group(group A),hemorrhagic shock group(group B) and Shengmai Injection treatment group(group C),each group had 10 rats.Rats of 3 groups were killed after operation in 3 days.The blood routine of rats were detected by automatic blood biochemistry analyzer,T lymphocytes and the content of CD3+,CD4+,CD8+ were detected by flow cytometry.Results Three day after injury,group B compared with group A,rat’s WBC and neutrophils obviously rised (8.890±0.387) ×109/L vs(4.230±0.856) ×109/L,P = 0],(26.15±2.97)% vs(16.00±4.53)%,P = 0],lympholeukocyte obviously decreased (68.57±5.23)% vs(76.617±4.9)%,P = 0.001].After treatment of Shengmai Injection,the rat’s WBC and neutrophils obviously decreased (6.29±0.758) ×109/L vs(8.89±0.387) ×109/L,P = 0] (20.29±3.09)% vs(68.57±5.23)%,P = 0.001],in the same time,lympholeukocyte obviously rised (74.85±4.12)% vs(76.617±4.9)%,P=0.007].After hemorrhagic shock,group B compared with group A,lympholeukocyte of CD3+,CD4+ antigen presentation expression obviously decreased CD3+:(31.17±4.00) vs(41.97±2.50),P = 0;CD4+:(10.49±1.42) vs(15.51±3.48),P = 0.003],CD4+/CD8+ has decreased (0.97±0.09) vs(1.19±0.07),P = 0),CD8+ has no change (17.75±5.94) vs(17.34±3.77),P = 0.997].After Shengmai Injection,the CD3+,CD4+ antigen presentation expression obviously increased CD3+:(36.64±5.73) vs(31.17±4.00),P = 0.001;CD4+:(10.49±1.42) vs(13.94±2.02),P = 0.008),CD4+/CD8+ has rised (1.12±0.03) vs(0.97±0.09),P = 0.001].Conclusion Shengmai Injection can elevate the immune ability of organism,and lighten the inflammation of body after severe trauma.
Keywords:Hemorrhagic shock after trauma  Shengmai Injection  lympholeukocyte  Immune
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号